SomaLogic, Inc. (SLGC): Price and Financial Metrics

SomaLogic, Inc. (SLGC): $2.29

-0.05 (-2.14%)

POWR Rating

Component Grades














  • SLGC scores best on the Value dimension, with a Value rank ahead of 78.64% of US stocks.
  • SLGC's strongest trending metric is Growth; it's been moving down over the last 177 days.
  • SLGC ranks lowest in Quality; there it ranks in the 6th percentile.

SLGC Stock Summary

  • SOMALOGIC INC's stock had its IPO on February 23, 2021, making it an older stock than only 8.03% of US equities in our set.
  • The ratio of debt to operating expenses for SOMALOGIC INC is higher than it is for about just 0.44% of US stocks.
  • Revenue growth over the past 12 months for SOMALOGIC INC comes in at 73.68%, a number that bests 90.01% of the US stocks we're tracking.
  • Stocks that are quantitatively similar to SLGC, based on their financial statements, market capitalization, and price volatility, are PAVM, IGC, MXCT, SMRT, and LNSR.
  • To dig deeper into the stock's financial statements, go to SLGC's page on browse-edgar?action=getcompany&CIK=0001837412.

SLGC Valuation Summary

  • SLGC's price/sales ratio is 4.3; this is 72% higher than that of the median Technology stock.
  • Over the past 25 months, SLGC's price/sales ratio has gone down 1.3.

Below are key valuation metrics over time for SLGC.

Stock Date P/S P/B P/E EV/EBIT
SLGC 2023-03-21 4.3 0.7 -5.3 -0.7
SLGC 2023-03-20 4.1 0.7 -5.0 -0.4
SLGC 2023-03-17 4.2 0.7 -5.2 -0.6
SLGC 2023-03-16 4.5 0.8 -5.6 -1.0
SLGC 2023-03-15 4.5 0.8 -5.5 -0.9
SLGC 2023-03-14 4.5 0.8 -5.5 -0.9

SLGC Stock Price Chart Interactive Chart >

Price chart for SLGC

SLGC Price/Volume Stats

Current price $2.29 52-week high $8.50
Prev. close $2.34 52-week low $1.98
Day low $1.98 Volume 3,269,700
Day high $2.31 Avg. volume 1,046,013
50-day MA $2.87 Dividend yield N/A
200-day MA $3.40 Market Cap 420.11M

SomaLogic, Inc. (SLGC) Company Bio

SomaLogic, Inc. operates as a protein biomarker discovery and clinical diagnostics company in the United States. It develops slow-offrate modified aptamers (SOMAmers), which are modified nucleic acid-based protein binding reagents that are specific for their cognate protein; and offers proprietary SomaScan services, which provide multiplex protein detection and quantification of protein levels in complex biological samples. The company's SOMAmers/SomaScan technology enables researchers to analyze various types of biological samples for protein biomarker signatures, which can be utilized in drug discovery and development. Its SomaScan's biomarker discoveries help in diagnostic applications in various areas of diseases, including cardiovascular and metabolic disease, nonalcoholic steatohepatitis, wellness, and others. The company's solutions also include SomaSignal tests, which are research use only tests for clinical trial applications. It serves research and clinical customers with a focus on pharmaceutical and biotechnology companies, and academic research institutions; and facilitates drug development, analysis of clinical trials, and new human biology insights by assessing protein-protein and protein-gene networks. The company was incorporated in 1999 and is headquartered in Boulder, Colorado.

SLGC Latest News Stream

Event/Time News Detail
Loading, please wait...

SLGC Latest Social Stream

Loading social stream, please wait...

View Full SLGC Social Stream

Latest SLGC News From Around the Web

Below are the latest news stories about SOMALOGIC INC that investors may wish to consider to help them evaluate SLGC as an investment opportunity.

SomaLogic, Inc. (SLGC) Q4 2022 Earnings Call Transcript

SomaLogic, Inc. (SLGC)

Q4 2022 Earnings Conference Call

March 27, 2023, 04:30 PM ET

Company Participants

Marissa Bych - Investor Relations, Gilmartin Group LLC

Troy Cox - Chief Executive Officer

Shaun Blakeman - Chief Financial Officer

Adam Taich - EVP, Life Sciences Business Unit

Conference Call Participants

Dan Brennan - Cowen

Kyle Mikson - Canaccord Genuity



Welcome to SomaLogic's Fourth Quarter and Full Year 2022 Earnings Call. All participants are in a listen-only mode. We will take questions following prepared remarks.

I will now turn the call over to Marissa Bych of Gilmartin Group for introductory disclosu...

SA Transcripts on Seeking Alpha | March 29, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

We're starting off Wednesday with a breakdown of the biggest pre-market stock movers traders will want to keep an eye on!

William White on InvestorPlace | March 29, 2023

SomaLogic Reports Fourth Quarter and Full Year 2022 Financial Results, Announces Director Appointments and Management Evolution

Adam Taich, EVP Life Sciences, promoted to interim CEO with a focus on operational executionBoard transition adds industry veterans: Jason Ryan as Chairman; Tycho Peterson, Kathy Hibbs, and Tom Carey as Independent DirectorsFourth quarter 2022 revenue of $18.8 million; full year 2022 revenue of $97.7 million Full year 2023 revenue guidance of $80-84 million, reflecting 12-17% growth over 2022, excluding licensing revenue from New England Biolabs Substantial balance sheet provides flexibility wit

Yahoo | March 28, 2023

Oxford Population Health and SomaLogic deliver 28 million proteomic data points on China Kadoorie Biobank samples

BOULDER, Colo., March 13, 2023 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in proteomics technology, recently completed the 7,000-plex assay on and delivered data for 4,000 plasma samples from the China Kadoorie Biobank (CKB), one of the world’s largest prospective studies. The SomaLogic team provided more than 28 million data points from the assay which will be combined with other available genetic, lifestyle, anthropometric and health outcome data to address a range of research questions. Th

Yahoo | March 13, 2023

SomaLogic to Announce Fourth Quarter and Full Year 2022 Financial Results

BOULDER, Colo., March 09, 2023 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in proteomics technology, today announced that it will report financial results for the fourth quarter and full year 2022 after market close on Tuesday, March 28, 2023. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Those interested in listening to the conference call should register online here. Participants are encouraged to register more than 15 minutes before the st

Yahoo | March 9, 2023

Read More 'SLGC' Stories Here

SLGC Price Returns

1-mo -9.84%
3-mo -8.76%
6-mo -21.03%
1-year -71.48%
3-year N/A
5-year N/A
YTD -8.76%
2022 -78.44%
2021 N/A
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7965 seconds.